{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAFLD%2FNASH+-+Placebo&page=2", "query": { "intervention": "NAFLD/NASH - Placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAFLD%2FNASH+-+Placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T17:11:57.884Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01529268", "title": "Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Nonalcoholic Fatty Liver Disease (NAFLD)" ], "interventions": [ { "name": "DR cysteamine bitartrate capsule", "type": "DRUG" }, { "name": "DR cysteamine bitartrate placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 169, "start_date": "2012-06", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 10, "location_summary": "San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01529268" }, { "nct_id": "NCT05733455", "title": "Effect of Alpelisib in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Hyperinsulinemia", "Dyslipidemias" ], "interventions": [ { "name": "Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)", "type": "DRUG" }, { "name": "Placebo (microcrystalline cellulose), 2 capsules", "type": "DRUG" }, { "name": "FreeStyle Libre Pro", "type": "DEVICE" }, { "name": "Oral glucose tolerance test (OGTT) with Trutol glucose beverage", "type": "DIAGNOSTIC_TEST" }, { "name": "BOOST Plus nutritional beverage", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DEVICE", "DIAGNOSTIC_TEST", "DIETARY_SUPPLEMENT" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2023-05-09", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733455" }, { "nct_id": "NCT04583423", "title": "A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "MK-3655", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 183, "start_date": "2020-11-11", "completion_date": "2023-04-13", "has_results": true, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 48, "location_summary": "Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583423" }, { "nct_id": "NCT04019561", "title": "A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-alcoholic Fatty Liver Disease (NAFLD)", "Non-alcoholic Steatohepatitis (NASH)" ], "interventions": [ { "name": "MEDI0382 high dose", "type": "DRUG" }, { "name": "Placebo for MEDI0382 high dose", "type": "DRUG" }, { "name": "MEDI0382 low dose", "type": "DRUG" }, { "name": "Placebo for MEDI0382 low dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 74, "start_date": "2019-09-23", "completion_date": "2021-05-06", "has_results": true, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 26, "location_summary": "Tucson, Arizona • Canoga Park, California • Chula Vista, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019561" }, { "nct_id": "NCT04048876", "title": "Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-alcoholic Fatty Liver Disease", "Liver Cirrhosis" ], "interventions": [ { "name": "CC-90001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-08-14", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 64, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04048876" }, { "nct_id": "NCT03459079", "title": "Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Fatty Liver Disease (NAFLD)", "Type 2 Diabetes (T2DM)" ], "interventions": [ { "name": "Lanifibranor", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 128, "start_date": "2018-08-14", "completion_date": "2023-06-01", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459079" }, { "nct_id": "NCT01002547", "title": "Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "pioglitazone-placebo", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" }, { "name": "Vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin E-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2010-06-24", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2018-09-11", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 2, "location_summary": "Gainesville, Florida • San Antonio, Texas", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01002547" }, { "nct_id": "NCT00681408", "title": "Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-alcoholic Steatohepatitis", "Fatty Liver" ], "interventions": [ { "name": "Omega 3 Fish Oil supplements", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 41, "start_date": "2007-03", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2015-05-29", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00681408" }, { "nct_id": "NCT03371355", "title": "Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NAFLD", "Diabetes Mellitus, Type 2", "Hypertriglyceridemia", "Fatty Liver, Nonalcoholic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ISIS 703802 40 mg", "type": "DRUG" }, { "name": "ISIS 703802 80 mg", "type": "DRUG" }, { "name": "ISIS 703802 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akcea Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2017-12-21", "completion_date": "2020-02-24", "has_results": true, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 38, "location_summary": "Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371355" }, { "nct_id": "NCT03617263", "title": "Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-alcoholic Fatty Liver Disease in Women With PCOS" ], "interventions": [ { "name": "Saroglitazar Magnesium 4 mg Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zydus Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 60, "start_date": "2019-02-12", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-09-28T17:11:57.884Z", "location_count": 13, "location_summary": "Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Panorama City", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617263" } ] }